Full-Time

Sr. Manager

Quality Control, Reference Standards

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$180k - $187kAnnually

Senior, Expert

San Carlos, CA, USA

Hybrid position.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Bachelor’s, Master’s, or Ph.D. in Biochemistry, Chemistry, or a related field. Ph.D. with 5+ years of relevant QC experience, or MS/BS with 8+ years of experience, including significant experience in reference standard management.
  • Strong background in cGMP and ICH regulatory guidance associated with reference standards and critical reagents.
  • Experience working with biochemistry, immunoassay, or microbiological assay techniques.
  • Familiarity with statistical software (e.g., JMP) for data analysis, trending, and process optimization.
  • Excellent organizational and project management skills, with the ability to handle multiple projects under tight timelines.
  • Strong written and verbal communication skills, including the ability to work effectively in cross-functional teams.
  • Proficiency in LIMS and other laboratory data management systems is preferred.
Responsibilities
  • Oversee the implementation and maintenance of the reference standards and critical reagent program, ensuring compliance with cGMP and ICH guidelines.
  • Support the development of global business practices, policies, and standards for reference standards and critical reagents, including qualification, requalification, and inventory management.
  • Collaborate in the authoring and review of technical protocols, qualification reports, requalification reports, and Certificates of Analysis (CoAs) related to reference standards. Ensure timely updates to SOPs and other relevant documentation.
  • Manage supply chain logistics, including inventory and space planning, to ensure a continuous supply of qualified reference standards and critical reagents.
  • Serve as a key point of contact within Vaxcyte QC and with external partners, fostering productive collaborations to support the company's vaccine programs.
  • Provide technical guidance on assay qualification and validation to meet regulatory standards, and review test methods and release documentation for reference standards.
  • Review and manage deviations, OOS/OOT results, and conduct risk assessments related to reference standards and critical reagents.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to improve global health outcomes, particularly for vulnerable populations.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

63%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Vaxcyte's VAX-24 has FDA Breakthrough Therapy designation, expediting its development.
  • Recent $1.5 billion public offering indicates strong investor confidence in Vaxcyte.
  • Growing demand for pneumococcal vaccines in emerging markets boosts Vaxcyte's market potential.

What critics are saying

  • Competition from Pfizer's Prevnar 20 could impact Vaxcyte's market share.
  • Reliance on XpressCF™ platform poses risks if technical challenges arise.
  • Emergence of new bacterial strains may reduce current vaccine effectiveness.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae.
  • Vaxcyte's vaccines aim to combat bacterial infections with broad-spectrum efficacy.

Help us improve and share your feedback! Did you find this helpful?